BR0013416A - Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado - Google Patents

Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado

Info

Publication number
BR0013416A
BR0013416A BR0013416-3A BR0013416A BR0013416A BR 0013416 A BR0013416 A BR 0013416A BR 0013416 A BR0013416 A BR 0013416A BR 0013416 A BR0013416 A BR 0013416A
Authority
BR
Brazil
Prior art keywords
drug
group
bisphosphonate
treating
fractured bone
Prior art date
Application number
BR0013416-3A
Other languages
English (en)
Portuguese (pt)
Inventor
David Graham Little
Original Assignee
Royal Alexandra Hosp Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Alexandra Hosp Children filed Critical Royal Alexandra Hosp Children
Publication of BR0013416A publication Critical patent/BR0013416A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0013416-3A 1999-08-19 2000-08-17 Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado BR0013416A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
PCT/AU2000/000982 WO2001013922A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures

Publications (1)

Publication Number Publication Date
BR0013416A true BR0013416A (pt) 2002-04-30

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013416-3A BR0013416A (pt) 1999-08-19 2000-08-17 Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado

Country Status (16)

Country Link
EP (1) EP1214079A4 (no)
JP (1) JP2003507426A (no)
KR (1) KR20020027562A (no)
CN (1) CN100345548C (no)
AU (1) AUPQ232599A0 (no)
BR (1) BR0013416A (no)
CA (1) CA2381302A1 (no)
HK (1) HK1048441B (no)
HU (1) HUP0202396A3 (no)
IL (1) IL148166A0 (no)
NO (1) NO20020784L (no)
NZ (1) NZ517538A (no)
PL (1) PL353485A1 (no)
SK (1) SK2382002A3 (no)
WO (1) WO2001013922A1 (no)
ZA (1) ZA200202160B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527351A (en) 2001-02-06 2005-01-28 Royal Alexandra Hosp Children Use of bisphosphonate for the treatment of osteonecrosis and for the management of patients at risk of developing ostenonecrosis
WO2002080933A1 (en) * 2001-04-03 2002-10-17 The Royal Alexandra Hospital For Children A drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
EP1508343B1 (en) * 2003-08-21 2015-11-04 AddBIO AB Bisphosponate coated implant device and method therefor
RU2326695C2 (ru) * 2003-09-19 2008-06-20 Пфайзер Продактс Инк. Фармацевтические композиции и способы, включающие комбинации 2-алкилиденовых производных 9-нор-витамина d и бисфосфоната
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
JP5426168B2 (ja) * 2005-10-27 2014-02-26 トーメン メディカル アーゲー 歯科インプラント及びその製造方法
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
RU2112515C1 (ru) * 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
AU703887B2 (en) * 1995-06-06 1999-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Also Published As

Publication number Publication date
ZA200202160B (en) 2003-08-27
PL353485A1 (en) 2003-11-17
WO2001013922A1 (en) 2001-03-01
HK1048441B (zh) 2008-02-22
HUP0202396A3 (en) 2005-02-28
CN100345548C (zh) 2007-10-31
EP1214079A1 (en) 2002-06-19
KR20020027562A (ko) 2002-04-13
CN1370071A (zh) 2002-09-18
SK2382002A3 (en) 2002-09-10
NZ517538A (en) 2003-07-25
CA2381302A1 (en) 2001-03-01
AUPQ232599A0 (en) 1999-09-09
NO20020784D0 (no) 2002-02-18
IL148166A0 (en) 2002-09-12
HK1048441A1 (en) 2003-04-04
JP2003507426A (ja) 2003-02-25
HUP0202396A2 (hu) 2002-11-28
NO20020784L (no) 2002-02-18
EP1214079A4 (en) 2004-03-24

Similar Documents

Publication Publication Date Title
ES2138067T3 (es) Proceso para el tratamiento de un implante quirurgico.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BR0014767A (pt) Fibras de sementes de plantas e uso
FI971974A (fi) Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö
BR0016058A (pt) Compostos de fosfonato
BR0107942A (pt) Polìmeros de proteìna de liberação lenta
BR0113184A (pt) Implante artificial e processo para produzir o mesmo
WO2002041837A3 (en) Treatment of mucositis
SE9901272D0 (sv) New improved formulation
BR0212809A (pt) Inibidores de anticorpos de gdf-8 e usos dos mesmos
AR005987A1 (es) Terapia combinada para la osteoporosis
PT938326E (pt) Fosfopeptidos de sintese para o tratamento de doencas dos ossos
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
BR0112350A (pt) Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
DE60233803D1 (de) 5-cnac zur oralen verabreichung von parathormonfragmenten
BR0212757A (pt) Composição, método para produzir uma composição de fator de crescimento, e, método para tratar um defeito de osso, tendão ou cartilagem
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
BR9811643A (pt) Suplementação quìmica de osso
ATE275580T1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REFERENTE A RPI NO 2011 DE 21/07/2009.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13, 10(VIII), 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.